Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry.

Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin.

Background: Since mutations in the mitochondrial genome are associated with hearing loss, we analyzed whether sequence variations of mtDNA are associated with individual sensitivity to cisplatin-induced ototoxicity.

Materials And Methods: The mtDNA of 20 patients with and 19 patients without hearing impairment under therapeutic doses of cisplatin was sequenced for mutations and characterized for haplotype by restriction analysis.

Results: Neither the A7445G mutation, nor the 7472insC insertion or the A1555G mutation were identified in any of the patients.

[Test set for the evaluation of hearing and speech development after cochlear implantation in children].

Background: Since autumn 1998 the multicenter interdisciplinary study group "Test Materials for CI Children" has been compiling a uniform examination tool for evaluation of speech and hearing development after cochlear implantation in childhood.

Methods Used: After studying the relevant literature, suitable materials were checked for practical applicability, modified and provided with criteria for execution and break-off. For data acquisition, observation forms for preparation of a PC-version were developed.

Acoustically and electrically evoked responses of the human cortex before and after cochlear implantation.

Multi-channel auditory evoked potentials (AEP) were recorded before and after cochlear implantation (CI) from a patient suffering from severe high frequency hearing loss with residual, but highly fluctuating hearing around 250 Hz. Immediately after CI activation early components of the N1 were present. Later N1 components developed during the use of CI.